{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-051517","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.509221+00:00","generated_at":"2026-06-03T08:25:24.890282+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Merck Q1 sales up 9% to $15.8B; raises FY2024 sales and EPS guidance","bullets":["GAAP EPS $1.87 (+68% YoY); Non-GAAP EPS $2.07 (+48% YoY). Sales $15.775B (+9%, +12% ex-FX).","Keytruda sales grew 20% to $6.9B; Gardasil sales up 14% to $2.2B on strong China demand.","Full-year 2024 sales outlook raised to $63.1-$64.3B; Non-GAAP EPS outlook raised to $8.53-$8.65.","Received FDA approval for WINREVAIR (PAH); closed Harpoon acquisition with $656M charge.","Proposed acquisition of Elanco's aqua business to broaden animal health portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-051517","json":"https://secwatch.observer/filing/0001104659-24-051517.json","markdown":"https://secwatch.observer/filing/0001104659-24-051517.md","text":"https://secwatch.observer/filing/0001104659-24-051517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465924051517/0001104659-24-051517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465924051517/tm2412490d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T08:25:24.890282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c723769b7ea088214c6fa4e86a04ba8de6403adb","claim":"Merck & Co., Inc. reported first quarter of 2024 results: revenue $15,775, net income 4,762, EPS GAAP EPS 1.87; Non-GAAP EPS that excludes certain items 2* 2.07. Guidance raised.","evidence_excerpt":"Financial Summary First Quarter $ in millions, except EPS amounts 2024 2023 Change Change Ex- Exchange Sales $ 15,775 $ 14,487 9 % 12 % GAAP net income 1 4,762 2,821 69 % 76 % Non-GAAP net income that excludes certain items 1,2* 5,279 3,564 48 % 54 % GAAP EPS 1.87 1.11 68 % 76 % Non-GAAP EPS that excludes certain items 2* 2.07 1.40 48 % 54 %","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465924051517/0001104659-24-051517-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"$15,775"},{"label":"Net income","value":"4,762"},{"label":"EPS","value":"GAAP EPS 1.87; Non-GAAP EPS that excludes certain items 2* 2.07"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}